RS62059B1 - Kompozicija implanta risperidona i/ili paliperidona - Google Patents

Kompozicija implanta risperidona i/ili paliperidona

Info

Publication number
RS62059B1
RS62059B1 RS20210834A RSP20210834A RS62059B1 RS 62059 B1 RS62059 B1 RS 62059B1 RS 20210834 A RS20210834 A RS 20210834A RS P20210834 A RSP20210834 A RS P20210834A RS 62059 B1 RS62059 B1 RS 62059B1
Authority
RS
Serbia
Prior art keywords
risperidone
implant formulation
paliperidone implant
paliperidone
formulation
Prior art date
Application number
RS20210834A
Other languages
English (en)
Inventor
Aduriz Ibon Gutierro
Rodriguez Guillermo Franco
Original Assignee
Laboratorios Farmaceuticos Rovi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62059(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/059001 external-priority patent/WO2011151356A2/en
Priority claimed from PCT/EP2011/059000 external-priority patent/WO2011151355A1/en
Application filed by Laboratorios Farmaceuticos Rovi S A filed Critical Laboratorios Farmaceuticos Rovi S A
Publication of RS62059B1 publication Critical patent/RS62059B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20210834A 2011-05-31 2012-05-31 Kompozicija implanta risperidona i/ili paliperidona RS62059B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/059001 WO2011151356A2 (en) 2010-05-31 2011-05-31 Methods for the preparation of injectable depot compositions
PCT/EP2011/059000 WO2011151355A1 (en) 2010-05-31 2011-05-31 Antipsychotic injectable depot composition
EP12170362.3A EP2529756B1 (en) 2011-05-31 2012-05-31 Risperidone and/or Paliperidone implant formulation

Publications (1)

Publication Number Publication Date
RS62059B1 true RS62059B1 (sr) 2021-07-30

Family

ID=46147376

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210834A RS62059B1 (sr) 2011-05-31 2012-05-31 Kompozicija implanta risperidona i/ili paliperidona

Country Status (30)

Country Link
EP (2) EP2529756B1 (sr)
JP (1) JP6367795B2 (sr)
KR (1) KR101880716B1 (sr)
CN (1) CN104363923A (sr)
AU (1) AU2013269547B2 (sr)
BR (1) BR112014029209A2 (sr)
CA (1) CA2874765C (sr)
CL (1) CL2014003216A1 (sr)
CO (1) CO7160108A2 (sr)
CY (1) CY1124369T1 (sr)
DK (1) DK2529756T3 (sr)
EA (1) EA031819B1 (sr)
ES (1) ES2878112T3 (sr)
HR (1) HRP20211057T1 (sr)
IL (1) IL235849B (sr)
IN (1) IN2014DN10672A (sr)
LT (1) LT2529756T (sr)
MA (1) MA37664B1 (sr)
MX (1) MX2014014483A (sr)
MY (1) MY174999A (sr)
NZ (1) NZ703321A (sr)
PH (1) PH12014502667A1 (sr)
PL (1) PL2529756T3 (sr)
PT (1) PT2529756T (sr)
RS (1) RS62059B1 (sr)
SG (1) SG11201407961WA (sr)
SI (1) SI2529756T1 (sr)
UA (1) UA119430C2 (sr)
WO (1) WO2013178812A1 (sr)
ZA (1) ZA201409299B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
MX354603B (es) 2007-05-25 2018-03-13 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
PL2529756T3 (pl) * 2011-05-31 2021-11-15 Laboratorios Farmaceuticos Rovi, S.A. Formulacja implantu zawierającego rysperydon i/lub paliperydon
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
CN104922085B (zh) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 一种利培酮植入剂及其制备方法
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP3801378A4 (en) 2018-05-24 2022-02-23 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013814A1 (en) 1993-11-19 1995-05-26 Janssen Pharmaceutica N.V. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
BRPI0513089B8 (pt) 2004-08-04 2021-05-25 Alza Corp forma de dosagem para liberação controlada de um fármaco de ordem ascendente de zero
DK2154138T3 (en) 2007-04-19 2015-11-02 Youxin Li Novel compounds for the treatment of psychotic disorders, methods of preparation and uses thereof
EP3115038A1 (en) * 2007-05-18 2017-01-11 DURECT Corporation Improved depot formulations
MX354603B (es) * 2007-05-25 2018-03-13 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
EP2178872A1 (en) 2007-07-27 2010-04-28 Synthon B.V. Paliperidone derivatives
LT2234617T (lt) 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Dozės režimai, susiję su ilgo veikimo injekuojamais paliperidono esteriais
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
HRP20211853T1 (hr) * 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
LT2394664T (lt) * 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
PL2529756T3 (pl) * 2011-05-31 2021-11-15 Laboratorios Farmaceuticos Rovi, S.A. Formulacja implantu zawierającego rysperydon i/lub paliperydon

Also Published As

Publication number Publication date
UA119430C2 (uk) 2019-06-25
AU2013269547A1 (en) 2015-01-22
PH12014502667B1 (en) 2015-02-02
CN104363923A (zh) 2015-02-18
IL235849B (en) 2019-03-31
LT2529756T (lt) 2021-07-26
EP2529756B1 (en) 2021-05-19
ES2878112T3 (es) 2021-11-18
MX2014014483A (es) 2015-02-24
ZA201409299B (en) 2015-12-23
IN2014DN10672A (sr) 2015-08-28
EP2529756A2 (en) 2012-12-05
HRP20211057T1 (hr) 2021-10-01
EP2854858A1 (en) 2015-04-08
EP2529756A3 (en) 2013-08-07
IL235849A0 (en) 2015-01-29
SI2529756T1 (sl) 2021-09-30
CL2014003216A1 (es) 2015-07-10
KR20150016964A (ko) 2015-02-13
PH12014502667A1 (en) 2015-02-02
PL2529756T3 (pl) 2021-11-15
MA37664B1 (fr) 2016-11-30
JP6367795B2 (ja) 2018-08-01
WO2013178812A1 (en) 2013-12-05
JP2015518036A (ja) 2015-06-25
NZ703321A (en) 2017-01-27
AU2013269547B2 (en) 2018-03-15
DK2529756T3 (da) 2021-08-02
CO7160108A2 (es) 2015-01-15
CY1124369T1 (el) 2022-07-22
KR101880716B1 (ko) 2018-08-17
SG11201407961WA (en) 2014-12-30
EA031819B1 (ru) 2019-02-28
EA201401346A1 (ru) 2015-04-30
MA37664A1 (fr) 2016-03-31
BR112014029209A2 (pt) 2017-06-27
PT2529756T (pt) 2021-07-28
CA2874765C (en) 2020-06-02
CA2874765A1 (en) 2013-12-05
MY174999A (en) 2020-06-01

Similar Documents

Publication Publication Date Title
HUE054922T2 (hu) Riszperidon és/vagy Paliperidon implantátum készítmény
RS62059B1 (sr) Kompozicija implanta risperidona i/ili paliperidona
ZA201409297B (en) Paliperidone implant formulation
HK1203367A1 (en) Medical organogel processes and compositions
HK1211930A1 (en) Haptens of risperidone and paliperidone
GB201400072D0 (en) Implant and implant system
GB201111438D0 (en) Formulation
ZA201309221B (en) Formulation
GB2486567B (en) Pharmaceutical formulation
IL228436A0 (en) Pyridopyrazine history and their use
PT2521445T (pt) Formulação e utilização da mesma
SG10201606161UA (en) Albumin Formulation and Use
GB201117106D0 (en) Prosthesis and methods and uses involving said prosthesis
ZA201402456B (en) Formulation
IL221087A (en) Pharmacy or nutritional composition
GB201006326D0 (en) Formulation
GB201106958D0 (en) Formulation
IL229936B (en) Albumin formulation and use
GB201019224D0 (en) Detoxification formulation
GB201217711D0 (en) Liquid oral rehydration formulation
GB201005992D0 (en) Formulation
GB201001978D0 (en) Formulation
GB201002000D0 (en) Formulation
GB201113314D0 (en) Formulations and processes
GB201112578D0 (en) Pharmaceutical preparation and use